Roche and Molecular Partners have entered into a research and licensing alliance to discover, develop and commercialize new cancer treatments. The agreement will incorporate Molecular Partners ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), ...

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...

Roche's pharmaceutical portfolio now includes ... The company plans to advance four new molecular entities with potential launches in 2026. Near Patient Care remains a strategic focus, supported ...

pathology and molecular solutions products. Sales grew 9% in the fourth quarter to CHF 15.5 billion. Roche’s shares have risen 10.6% year to date against the industry’s decline of 1.2%.

Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and Molecular Partners AG. According to TipRanks, Vosser has an average return of 4.2% and a 49.47% ...

“Rapid molecular point-of-care testing can revolutionise ... said Matt Sause, CEO Roche Diagnostics. More than 1 million people worldwide acquire an STI every day. Common STIs often present ...

including six from the U.S., as well as 72 new partnerships, including four acquisitions. For 2025, Roche expects 12 key pivotal trial readouts, including four new molecular entities.

Roche, via their African Genomics Program ... Gordon Awandare, Professor of Biochemistry, Cell and Molecular Biology and Pro-Vice Chancellor of the University of Ghana. “Through partnerships like TACA ...